Vertex Pharmaceuticals

Open: 350.0 Close: 358.4 Change: 8.4

Our AI found some flaws in Vertex Pharmaceuticals.

Are looking for the most relevant information about Vertex Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Vertex Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, stock, earnings, high, Bernstein, sale, and the most common words in the summary are: vertex, pharmaceutical, stock, vrtx, company, job, news, . One of the sentences in the summary was: CEO Reshma Kewalramani sold 7,828 shares of the business.. Other searches …

Concept Map

Semantic Network

Stock Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis (CF) It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with.

Today's Summary

Vertex Pharmaceuticals raises full-year sales forecast on Tuesday, banking on strong demand for cystic fibrosis treatment strength. CEO Reshma Kewalramani sold 7,828 shares of the business.

Today's News

Vertex Pharmaceuticals raised full-year sales forecast on Tuesday, banking on strong demand for cystic fibrosis treatment strength. Analyst Consensus: Buy Stock Forecasts: Buy stock. Vertex Pharmaceuticals develops small molecule drugs for serious diseases. The following companies are expected to report after-hours earnings. Vertex Pharmaceuticals posted higher second-quarter earnings, boosted by higher cystic fibrosis drug revenue. The revenue for VX-548 is expected to reach an annual total of $157 mn by 2033 in the US. Vertex Pharmaceuticals Inc reported earnings per share of $3.88 and sales of $2.5 billion for the current quarter. CEO Reshma Kewalramani sold 7,828 shares of the businesss stock. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. The total value of the stock (marketization) is $89.56B. Competitor s include Pfizer , Sanofi and AbbVie. On Tuesday 08/01/2023 the closing price of the Vertex Pharmaceuticals Inc. was $351.42, this is a gain of 1.95%. The high in the last 52 weeks of Vertex. Pharmaceuticals stock has received a consensus rating of buy. Bernstein Maintains Vertex Pharmaceuticals (VRTX) Outperform Recommendation Bernstein Maintain. Bernstein maintained coverage of Vertex. Pharmaceuticals.

Stock Profile

"Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."

Keywords

This document will help you to evaluate Vertex Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, stock, earnings, high, Bernstein, sale, and the most common words in the summary are: vertex, pharmaceutical, stock, vrtx, company, job, news, . One of the sentences in the summary was: CEO Reshma Kewalramani sold 7,828 shares of the business.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #vertex #pharmaceutical #stock #vrtx #company #job #news.